Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07542548 · ClinicalTrials.gov registry record · Phase 4
D-Cycloserine for Serine Palmitoyltransferase Inhibition
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT07542548: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT07542548 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07542548, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The overarching objective of this study is to mitigate the neurological decline associated with SPTSSA related Complex Hereditary Spastic Paraplegia
Interventions
- DRUG D-cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-07-10 |
| Est. Completion | 2026-03-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07542548
The ClinicalTrials.gov registry entry for NCT07542548 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which D-cycloserine is the first listed.
NCT07542548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07542548 about?
NCT07542548 is a clinical study titled "D-Cycloserine for Serine Palmitoyltransferase Inhibition". The overarching objective of this study is to mitigate the neurological decline associated with SPTSSA related Complex Hereditary Spastic Paraplegia
What is the current status of trial NCT07542548?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2024-07-10. Estimated completion is 2026-03-17.
What interventions are being tested in trial NCT07542548?
The interventions under investigation include: D-cycloserine (DRUG).
Who is sponsoring clinical trial NCT07542548?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.